Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients

Even though male breast cancer (MBC) risk encompasses both genetic and environmental aetiologies, the primary risk factor is a germline pathogenic variant (PV) or likely pathogenic variant (LPV) in BRCA2, BRCA1 and/or PALB2 genes. To identify new potential MBC-specific predisposition genes, we sequenced a panel of 585 carcinogenesis genes in an MBC cohort without BRCA1/BRCA2/PALB2 PV/LPV. We identified 14 genes carrying rare PVs/LPVs in the MBC population versus noncancer non-Finnish European men, predominantly coding for DNA repair and maintenance of genomic stability proteins. We identified for the first time PVs/LPVs in PRCC (pre-mRNA processing), HOXA9 (transcription regulation), RECQL4 and WRN (maintenance of genomic stability) as well as in genes involved in other cellular processes. To study the specificity of this MBC PV/LPV profile, we examined whether variants in the same genes could be detected in a female breast cancer (FBC) cohort without BRCA1/BRCA2/PALB2 PV/LPV. Only 5/109 women (4.6%) carried a PV/LPV versus 18/85 men (21.2%) on these genes. FBC did not carry any PV/LPV on 11 of these genes. Although 5.9% of the MBC cohort carried PVs/LPVs in PALLD and ERCC2, neither of these genes were altered in our FBC cohort. Our data suggest that in addition to BRCA1/BRCA2/PALB2, other genes involved in DNA repair/maintenance or genomic stability as well as cell adhesion may form a specific MBC PV/LPV signature.

[1]  B. Bonanni,et al.  Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study. , 2023, European journal of cancer.

[2]  Ying Sun,et al.  Whole-exome sequencing study of familial nasopharyngeal carcinoma and its implication for identifying high-risk individuals. , 2022, Journal of the National Cancer Institute.

[3]  M. Scheurer,et al.  Cancer risk among RECQL4 heterozygotes. , 2022, Cancer genetics.

[4]  M. Cebrián,et al.  Epidemiologic evidence of exposure to polycyclic aromatic hydrocarbons and breast cancer: A systematic review and meta-analysis. , 2021, Chemosphere.

[5]  Yang Zhang,et al.  Molecular regulators of HOXA9 in acute myeloid leukemia , 2021, The FEBS journal.

[6]  D. Carraro,et al.  Genetic Landscape of Male Breast Cancer , 2021, Cancers.

[7]  R. Braren,et al.  PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer , 2021, Zeitschrift für Gastroenterologie.

[8]  C. Lázaro,et al.  BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort , 2021, Genes.

[9]  Xin Hu,et al.  Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk , 2020, Annals of translational medicine.

[10]  T. Sellami-Boudawara,et al.  Identification of novel candidate genes by exome sequencing in Tunisian familial male breast cancer patients , 2020, Molecular Biology Reports.

[11]  A. Ashworth,et al.  Common Susceptibility Loci for Male Breast Cancer , 2020, Journal of the National Cancer Institute.

[12]  G. Martinelli,et al.  Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients , 2020, Diagnostics.

[13]  A. Félix,et al.  Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer , 2020, International journal of molecular sciences.

[14]  M. Somerfield,et al.  Management of Male Breast Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Arveux,et al.  Prevalence of patients hospitalised for male breast cancer in France using the French nationwide hospital administrative database. , 2019, European journal of cancer care.

[16]  B. Bonanni,et al.  Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy , 2019, International journal of cancer.

[17]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[18]  F. Fostira,et al.  Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer , 2018, Breast Cancer Research and Treatment.

[19]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[20]  James T. Robinson,et al.  Variant Review with the Integrative Genomics Viewer. , 2017, Cancer research.

[21]  Melissa P. Murray,et al.  Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Hongtao Li,et al.  Association between the ERCC2 Asp312Asn polymorphism and risk of cancer , 2017, Oncotarget.

[23]  F. Couch,et al.  Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results , 2016, Breast Cancer Research and Treatment.

[24]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[25]  R. Kosaki,et al.  Constructive rescue of TFIIH instability by an alternative isoform of XPD derived from a mutated XPD allele in mild but not severe XP-D/CS , 2015, Journal of Human Genetics.

[26]  W. Willett,et al.  Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. , 2014, Journal of the National Cancer Institute.

[27]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[28]  M. El-Sibai,et al.  Palladin regulation of the actin structures needed for cancer invasion , 2014, Cell adhesion & migration.

[29]  M. Ringnér,et al.  The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer , 2013, PloS one.

[30]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[31]  R. Monnat,et al.  Spectrum and Risk of Neoplasia in Werner Syndrome: A Systematic Review , 2013, PloS one.

[32]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[33]  M. Ringnér,et al.  High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer , 2011, Breast Cancer Research and Treatment.

[34]  J. Bergh,et al.  Multidisciplinary meeting on male breast cancer: summary and research recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Landi.  Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. , 2009, Mutation research.

[36]  Gretchen L. Gierach,et al.  Prospective evaluation of risk factors for male breast cancer. , 2008, Journal of the National Cancer Institute.

[37]  M. Bronner,et al.  Palladin Mutation Causes Familial Pancreatic Cancer and Suggests a New Cancer Mechanism , 2006, PLoS medicine.

[38]  H. Nakagawa,et al.  Two new XPD patients compound heterozygous for the same mutation demonstrate diverse clinical features. , 2005, The Journal of investigative dermatology.

[39]  Helen Swede,et al.  Epidemiology of male breast cancer. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[40]  R. Mariani-Costantini,et al.  A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer? , 2004, European journal of cancer.

[41]  G. Hortobagyi,et al.  Breast carcinoma in men , 2004, Cancer.

[42]  R. Dahiya,et al.  Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. , 2002, Biochemical and biophysical research communications.

[43]  A. G. Kessel,et al.  Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  OUP accepted manuscript , 2022, Human Molecular Genetics.

[45]  Ali Jad Abdelwahab Yousef.  Male Breast Cancer: Epidemiology and Risk Factors. , 2017, Seminars in oncology.

[46]  Jie Liu,et al.  Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis , 2014, Molecular Genetics and Genomics.

[47]  L. Brinton,et al.  Is Male Breast Cancer Similar or Different than Female Breast Cancer? , 2004, Breast Cancer Research and Treatment.

[48]  D. Danks,et al.  DNA repair characteristics and mutations in the ERCC2 DNA repair and transcription gene in a trichothiodystrophy patient , 1997, Human mutation.